The RET ("rearranged during transfection") proto-oncogene encodes a receptor tyrosine kinase also known as cadherin family member 12 (CDHF12), cadherin-related family member 16 (CDHR16), Hirschsprung disease 1, PTC, MTC1, HSCR1, MEN2A, MEN2B, RET51, and RET-ELE1. Alternative splicing of the RET gene results in three isoforms of the Ret protein. These contain 51, 43, and 9 amino acids in their C-terminal sections and are designated Ret-51, Ret-43, and Ret-9, respectively. The extracellular domain of Ret protein contains a cadherin-like domain and several N-terminal glycosylation sites. The fully glycosylated Ret protein is reported to have a molecular weight of 170 kDa; other isoforms are reported as 150 kDa and 190 kDa. The RET gene plays an essential role in neural crest development. Mutations in the RET gene are associated with several types of endocrine neoplasia, Hirschsprung disease, and medullary thyroid carcinoma.
These products are affinity-purified IgG antibodies that recognizes human c-Ret long isoform (Cat.# 18128) and C-terminus (Cat.# 18121). The antibodies were raised in rabbit using synthetic c-Ret peptides, and can be used for Western blot (WB) detection, immunohistochemical (IHC) detection, or immunoprecipitation (IP) of human c-Ret proteins.